CareDx To Participate in Upcoming Jefferies Healthcare Conference
06/02/2022 - 04:01 PM
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the Company will participate in the Jefferies Healthcare Conference on June 9 th , 2022.
CareDx’s management is scheduled to present at the Jefferies Healthcare Conference on Thursday, June 9 th , 2022, at 2:00 PM ET . To listen to the webcast, please visit the investor relations section of CareDx’s website at: investors.caredxinc.com .
About CareDx – The Transplant Company
CareDx, Inc. , headquartered in South San Francisco, California , is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com .
View source version on businesswire.com : https://www.businesswire.com/news/home/20220602005866/en/
CareDx, Inc.
Sasha King
sking@CareDx.com
Investor Relations
Ian Cooney
investor@CareDx.com
Source: CareDx, Inc.
CDNA Rankings
#5231 Ranked by Stock Gains
CDNA Stock Data
Industry
Medical Laboratories
Sector
Health Care and Social Assistance
Tags
Health Technology, Medical Specialties, Health Care and Social Assistance, Medical Laboratories
Country
US
City
South San Francisco
About CDNA
caredx: transforming transplant patient care through novel surveillance management solutions caredx, inc. is dedicated to improving the lives of organ transplant patients through non-invasive diagnostics. by combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, caredx is at the forefront of organ transplant surveillance and pre-transplant hla typing solutions. nasdaq:cdna about allosure® allosure is the first and only non-invasive blood test that directly measures allograft injury and identifies the probability of active rejection to better manage kidney transplant patients. allosure is a clinical-grade, proprietary next-generation sequencing (ngs) based test to detect donor-derived cell-free dna (dd-cfdna) in order to identify organ injury in kidney transplant recipients. allosure is analytically validated as a sensitive, specific, and precise measurement of dd-cfdna. allos
